Tarsus prices $100M public offering of common stock and pre-funded warrants at $32/share

Tarsus Pharmaceuticals, Inc.

Offering consists of 2,812,500 shares common stock at $32.00/share and pre-funded warrants for 312,500 shares at $31.9999 each.
Underwriters granted 30-day option to purchase up to 468,750 additional shares at $32.00 less discounts.
Gross proceeds ~$100M; net proceeds expected ~$93.7M after discounts and expenses.
Offering expected to close March 5, 2024, subject to customary conditions.
Goldman Sachs, BofA, Guggenheim, and Oppenheimer are joint book-running managers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tarsus Pharmaceuticals, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC valued at expected to be approximately $93.7 million (effective 2024-02-29).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC
Value: expected to be approximately $93.7 million
Effective: 2024-02-29

Exact text from the filing

On February 29, 2024, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 2,812,500 shares of the Company’s common stock, par value $0.0001 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of its common stock (the “Offering”).

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-056209

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.